病毒学双语版Cha(2)

1、Chapter 6: InfectionSlide 1/38Infection:Part 2 Part 1Chapter 6: InfectionSlide 2/38Evasion of Immune Responses by VirusesCTLs can only respond to foreign antigens presented by MHC I complexes on the target cell.A number of viruses interfere with MHC I expression or function to disrupt this process &

2、amp; evade the CTL response.Such mechanisms include downregulation of MHC I expression by adenoviruses & interference with the antigen processing required to form an MHC I-antigen complex by herpesviruses.Chapter 6: InfectionSlide 3/38Evasion of Immune Responses by VirusesMHC-II antigens are ess

3、ential in the adaptive immune response in order to stimulate the development of antigen-responsive clones of effector cells.Herpesviruses & papillomaviruses interfere with the processing & surface expression of MHC II-antigen complexes, inhibiting the CTL response.The poxvirus Molluscum cont

4、agiosum encodes a homologue of MHC I which is expressed on the surface of infected cells but is unable to bind an antigenic peptide, thus avoiding killing by NK cells which would be triggered by the absence of MHC I on the cell surface.Similar proteins are made by other viruses such as HHV-5 (CMV),

5、& herpesviruses in general appear to have a number of sophisticated mechanisms to avoid NK cell killing.Chapter 6: InfectionSlide 4/38Evasion of Immune Responses by VirusesCytokines are secreted polypeptides that co-ordinate important aspects of the immune response, including inflammation, cellu

6、lar activation, proliferation, differentiation, & chemotaxis.Some viruses are able to inhibit the expression of certain chemokines directly.Herpesviruses & poxviruses encode viroceptors - virus homologs of host cytokine receptors which compete with cellular receptors for cytokine binding but

7、 fail to give trans-membrane signals.High-affinity binding molecules may also neutralize cytokines directly, & molecules known as virokines block cytokine receptors again without activating the intracellular signalling cascade.Chapter 6: InfectionSlide 5/38Evasion of Immune Responses by VirusesE

8、pstein-Barr virus EBER RNAs are similar in structure & function to the adenovirus VA RNAs.The EBNA-2 protein also blocks interferon-induced signal transductionVaccinia virus is known to show resistance to the antiviral effects of interferons.One of the early genes of this virus, K3L, encodes a p

9、rotein which is homologous to eIF-2 which inhibits the action of PKR. In addition, the E3L protein also binds dsRNA & inhibits PKR activationPoliovirus infection activates a cellular inhibitor of PKR in virus-infected cellsReovirus capsid protein 3 is believed to sequester dsRNA & therefore

10、prevent activation of PKRChapter 6: InfectionSlide 6/38Evasion of Immune Responses by VirusesAlthough direct humoral immunity is less significant than cell-mediated immunity, the anti-viral action of ADCC & complement make this a worthwhile target to inhibit.The most frequent means of subverting

11、 the humoral response is by high frequency genetic variation of the B cell epitopes on antigens to which antibodies bind.This is only possible for viruses which are genetically variable, e.g. influenza virus & HIV.Herpesviruses use alternative strategies such as encoding viral Fc receptors to pr

12、event Fc-dependent immune activation.Chapter 6: InfectionSlide 7/38Evasion of Immune Responses by VirusesPoxviruses, herpesviruses & retrovirus families encode mimics of normal regulators of complement activation proteins, e.g. secreted proteins which block C3 convertase assembly & accelerat

13、e its decay.Poxviruses can also inhibit C9 polymerization, preventing membrane permeabilization.Chapter 6: InfectionSlide 8/38Virus-Host InteractionsFor all viruses, pathogenic or non-pathogenic, the first factor which influences the course of infection is the mechanism & site of entry into the

14、body:Macintosh PICTim age form atis not supportedChapter 6: InfectionSlide 9/38The Skin:Mammalian skin is a highly effective barrier against viruses.The outer layer (epidermis) consists of dead cells & therefore does not support virus replication.Very few viruses infect directly by this route un

15、less there is prior injury such as minor trauma or puncture of the barrier, such as insect or animal bites or subcutaneous injections.Some viruses which do use this route are herpes simplex virus & papillomaviruses, although these viruses probably still require some form of disruption of the ski

16、n such as small abrasions or eczema.Chapter 6: InfectionSlide 10/38Mucosal Membranes:The mucosal membranes of the eye & genitourinary (GU) tract are much more favourable routes of access for viruses to the tissues of the body.This is reflected by the number of viruses which can be sexually trans

17、mitted; virus infections of the eye are also quite common.Chapter 6: InfectionSlide 11/38The Alimentary Canal:Viruses may infect the alimentary canal via the mouth, oropharynx, gut, or rectum, although viruses which infect the gut via the oral route must survive passage through the stomach, an extre

18、mely hostile environment with a very low pH & high concentrations of digestive enzymes.The gut is a highly valued prize for viruses - the intestinal epithelium is constantly replicating & there is a good deal of lymphoid tissue associated with the gut which provides many opportunities for vi

19、rus replication.Moreover, the constant intake of food & fluids provides ample opportunity for viruses to infect these tissues.To counteract this problem, the gut has many specific (e.g. secretory antibodies) & non-specific (e.g. stomach acids & bile salts) defence mechanisms.Chapter 6: I

20、nfectionSlide 12/38The Respiratory Tract:The respiratory tract is probably the most frequent site of virus infection.As with the gut, it is constantly in contact with external virus particles which are taken in during respiration.As a result, the respiratory tract also has defences aimed at virus in

21、fection - filtering of particulate matter in the sinuses, & cells & antibodies of the immune system present in the lower regions.Viruses which infect the respiratory tract usually come directly from the respiratory tract of others, since aerosol spread is very efficient: coughs & sneezes

22、 spread diseases.Chapter 6: InfectionSlide 13/38The Natural Environment is a Considerable Barrier to Virus Infections.Most viruses are relatively sensitive to heat, drying, ultraviolet light (sunlight), etc, although a few types are quite resistant to these factors.This is particularly important for

23、 viruses which are spread via contaminated water or foodstuffs - not only must they be able to survive in the environment until they are ingested by another host, but as most are spread by the faecal-oral route, they must also be able to pass through the stomach to infect the gut before being shed i

24、n the faeces.One way of overcoming environmental stress is to take advantage of a secondary vector for transmission between the primary hosts.Chapter 6: InfectionSlide 14/38Insect Vectors Offer Protection from the EnvironmentM acintosh PIC Tim age form atis not supportedChapter 6: InfectionSlide 15/

25、38Virus TransmissionViruses without a secondary vector must rely on continued host-to-host transmission, & have evolved various strategies to do this: The direct host-to-host transmission of viruses.This strategy relies on a high rate of infection to maintain the virus population The transmissio

26、n of the virus from one generation of hosts to the next.This may occur by infection of the foetus before, during, or shortly after birth (e.g. during breastfeeding).More rarely, it may involve direct transfer of the virus via the germ line itself, e.g. retroviruses.In contrast to horizontal transmis

27、sion, this strategy relies on long-term persistence of the virus in the host rather than rapid propagation & dissemination of the virus.Chapter 6: InfectionSlide 16/38Primary ReplicationHaving gained entry to a potential host, the virus must initiate an infection by entering a susceptible cell (

28、primary replication).This initial interaction frequently determines whether the infection will remain localized at the site of entry or spread to become a systemic infection.In some cases, virus spread is controlled by infection of polarized epithelial cells & the preferential release of virus f

29、rom either the apical (e.g. influenza virus - a localized infection in the upper respiratory tract) or basolateral (e.g. rhabdoviruses - a systemic infection) surface of the cells.Chapter 6: InfectionSlide 17/38Infection of Polarized EpitheliumMacintosh PICTimage formatis not supportedChapter 6: Inf

30、ectionSlide 18/38Systemic SpreadFollowing primary replication at the site of infection, the next stage may be spread throughout the host.In addition to direct cell-cell contact, there are two main mechanisms for spread throughout the host: Viruses may get into the bloodstream by direct inoculation,

31、for example, by arthropod vectors, blood transfusion, or intravenous drug abuse (sharing of non-sterilized needles). Spread of virus to the nervous system is usually preceded by primary viraemia.Chapter 6: InfectionSlide 19/38Clearance vs. PersistanceVirus clearance is mediated by the immune system.

32、However, viruses are moving targets which rapidly respond to pressure from the immune system by altering their antigenic composition (whenever possible).The classic example of this phenomenon is influenza virus, which displays two genetic mechanisms that allow the virus to alter its antigenic consti

33、tution: This involves the gradual accumulation of minor mutations (e.g. nucleotide substitutions) in the virus genome which result in subtly altered coding potential & therefore altered antigenicity, leading to decreased recognition by the In this process a sudden & dramatic change in the an

34、tigenicity of a virus occurs owing to reassortment of the segmented virus genome with another genome of a different antigenic type.Chapter 6: InfectionSlide 20/38Antigenic Variation in Influenza VirusM a c in to s h P IC Tim a g e fo r m a tis n o t s u p p o r te dMacintosh PICTimage formatis not s

35、upportedM a c i n t o s h P I C Ti m a g e f o r m a ti s n o t s u p p o r t e dChapter 6: InfectionSlide 21/38InfluenzaPandemicsM a c in to s h P IC Tim a g e fo r m a tis n o t s u p p o r te dChapter 6: InfectionSlide 22/38The Course of Virus InfectionsAbortive infection: occurs when a virus inf

36、ects a cell (or host), but cannot complete the full replication cycle. Therefore, this is a non-productive infection.Acute infection: many common virus infections (e.g. colds) - relatively brief infections, where the virus is usually eliminated completely by the immune system.Chronic infection: Thes

37、e are the converse of acute infections, i.e. prolonged & stubborn. The best studied example is lymphocytic choriomeningitis virus (LCMV, an arenavirus) infection in mice.Latent virus infections typically persist for the entire life of the host, e.g. herpes simplex virus (HSV).Chapter 6: Infectio

38、nSlide 23/38Chronic LCMV Infection:Macintosh PICTimage formatis not supportedM acintosh PIC Tim age form atis not supportedMacintosh PICTimage formatis not supportedMacintosh PICTimage formatis not supportedChapter 6: InfectionSlide 24/38Prevention & Therapy of Virus InfectionsThere are two aspe

39、cts of the response to the threat of virus diseases: prevention of infection & treatment of disease.The former strategy relies on two approaches: public & personal hygiene, which perhaps plays the major role in preventing virus infection (e.g. provision of clean drinking water & disposal

40、 of sewage; good medical practice such as the sterilization of surgical instruments) & vaccination, which makes use of the immune system to combat virus infections.Most of the damage to cells during virus infections occurs very early, often before the clinical symptoms of disease appear.This mak

41、es the treatment of virus infection very difficult, & therefore, in addition to being cheaper, prevention of virus infection is undoubtedly better than cure.Chapter 6: InfectionSlide 25/38Virus Vaccine DesignTo design effective vaccines, it is important to understand both the immune response to

42、virus infection & the stages of virus replication that are appropriate targets for immune intervention.To be effective, vaccines must stimulate as many of the bodys defence mechanisms as possible.In practice, this usually means trying to mimic the disease, without of course causing pathogenesis

43、- for example, the use of nasally administered influenza vaccines & orally administered poliovirus vaccines.To be effective, it is not necessary to get 100% uptake of vaccine.Herd immunity results from the break in transmission of a virus which occurs when a sufficiently high proportion of a pop

44、ulation has been vaccinated.This strategy is most effective where there is no alternative host for the virus, e.g. measles, & in practice is the situation that usually occurs since it is impossible to achieve 100% coverage with any vaccine.Chapter 6: InfectionSlide 26/38DNA Vaccines These are th

45、e newest type of vaccine & consist of only a DNA molecule encoding the antigen(s) of interest & possibly, costimulatory molecules such as cytokines. The concept behind these vaccines is that the DNA component will be expressed in vivo, creating small amounts of antigenic protein which serve

46、to prime the immune response so that a protective response can be rapidly generated when the real antigen is encountered. In theory, these vaccines could be manufactured quickly & should efficiently induce both humoral & cell-mediated immunity.Chapter 6: InfectionSlide 27/38Subunit VaccinesT

47、hese consist of only some components of the virus, sufficient to induce a protective immune response but not enough to allow any danger of infection.In general terms, they are completely safe, except for very rare cases in which adverse immune reactions may occur.Unfortunately, at present, they are

48、also the least effective & most expensive type of vaccines.The major technical problems associated with subunit vaccines are their relatively poor antigenicity & the need for new delivery systems, such as improved carriers & adjuvants.Synthetic vaccines, such as short, chemically synthes

49、ized peptides.Recombinant vaccines, produced by genetic engineering.Virus vectors, i.e. recombinant virus genomes genetically manipulated to express protective antigens from (unrelated) pathogenic viruses.Chapter 6: InfectionSlide 28/38Inactivated VaccinesProduced by exposing the virus to a denaturi

50、ng agent under precisely controlled conditions. The objective is to cause loss of virus infectivity without loss of antigenicity.Inactivated vaccines have certain advantages, such as generally being effective immunogens (if properly inactivated), being relatively stable, & carrying little or no

51、risk of vaccine-associated virus infection (if properly inactivated).It is not possible to produced inactivated vaccines for all viruses, since denaturation of virus proteins may lead to loss of antigenicity, e.g. measles virus.Although relatively effective, killed vaccines are sometimes not as effe

52、ctive at preventing infection as live virus vaccines, often because they fail to stimulate protective mucosal & cell-mediated immunity to the same extent.These vaccines may contain virus nucleic acids, which may themselves be a source of infection, either of their own accord (e.g. (+)sense RNA v

53、irus genomes) or after recombination with other viruses.Chapter 6: InfectionSlide 29/38Live (Attenuated) Virus VaccinesAttenuated viruses with reduced pathogenicity stimulate an immune response without causing disease.The vaccine strain may be a naturally occurring virus (e.g. use of cowpox virus by

54、 Edward Jenner to vaccinate against smallpox) or artificially attenuated in vitro (e.g. oral poliomyelitis vaccine produced by Albert Sabin).The advantage of attenuated vaccines is that they are good immunogens & induce long-lived, appropriate immunity.These vaccines may be biochemically & g

55、enetically unstable & may either lose infectivity or revert to virulence unexpectedly.Despite intensive study, it is not possible to produce an attenuated vaccine to order, & there is no general mechanism by which all viruses can be reliably & safely attenuated.Inappropriate use of live

56、virus vaccines, for example, in immunocompromised hosts or during pregnancy, may lead to vaccine-associated disease, whereas the same vaccine given to a healthy individual may be perfectly safe.Chapter 6: InfectionSlide 30/38Virus Vectors & Gene TherapyViruses are being developed as gene deliver

57、y systems for the treatment of inherited & also acquired diseases.The first human trial to treat children with immunodeficiency resulting from a lack of the enzyme adenosine deaminase (ADA) began in 1990 & showed encouraging results. Like most of the initial attempts, this trial used recombi

58、nant retrovirus genomes as vectors.A variety of different viruses are now being tested as potential vectors & a large number of different trials are underway.Non-virus methods of gene delivery including liposome/DNA complexes, peptide/DNA complexes & direct injection of recombinant DNA are a

59、lso under active investigation.Chapter 6: InfectionSlide 31/38Chemotherapy of Virus InfectionsThe alternative to vaccination is to attempt to treat virus infections using drugs which block virus replication.Historically, discovery of antiviral drugs has been largely fortuitous.Spurred on by successe

60、s in the treatment of bacterial infections with antibiotics, drug companies launched huge blind-screening programmes to identify chemical compounds with antiviral activity, with relatively little success.The key to the success of any antiviral drug lies in its specificity.Almost any stage of virus replication can be a target for a drug, but the drug must be more toxic to the virus than the host.Chapter 6: InfectionSlide 32/38Any of the Stages of Virus Replication can be A Target for Antiviral Intervention.The phase of replication can be i